VistaGen Therapeutics Receives Notices of Allowance in Australia and Japan for AV-101 Patents Covering Treatment of Depression Nov 12, 2018
VistaGen Therapeutics Acquires Worldwide Rights to Develop and Commercialize PH10, a First-in-Class Intranasally Administered Neuroactive Steroid with Rapid-onset Antidepressant Effects for Major Depressive Disorder Demonstrated in Phase 2a Study Oct 25, 2018
VistaGen Therapeutics to Present at Credit Suisse 27th Annual Healthcare Conference on Wednesday, November 14, 2018 Oct 22, 2018
VistaGen Therapeutics Appoints Dr. Michael Liebowitz to CNS Clinical and Regulatory Advisory Board in Preparation for Pivotal Phase 3 Development of PH94B as the First Rapid-Acting, On-Demand Treatment of Social Anxiety Disorder Oct 15, 2018
VistaGen Therapeutics Receives FDA Fast Track Designation for Development of AV-101 as a Non-Opioid Treatment for Neuropathic Pain Oct 3, 2018
VistaGen Therapeutics Acquires Worldwide License of Phase 3-Ready CNS Drug Candidate from Pherin Pharmaceuticals for As-Needed Treatment of Social Anxiety Disorder Sep 13, 2018
VistaGen Therapeutics and Baylor College of Medicine Collaborate on First-Step Study to Test VistaGen’s AV-101 for Potential Anti-Suicidal Effects in Veterans Aug 13, 2018
VistaGen Therapeutics Reports Fiscal Year 2018 Financial Results and Provides Year-to-Date Highlights Jun 26, 2018
